BionTech | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Friday
February 03, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
FRIDAY, FEBRUARY 03, 2023

BionTech

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
World+Biz

BioNTech starts human trial to test malaria vaccine

Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

Pfizer, BioNTech start Covid-flu combination vaccine study

Photo: Collected
Health

Cancer vaccine may be ready by 2030, say founders of Covid-19 vaccine maker BioNTech

Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
Coronavirus chronicle

BioNTech, Pfizer to start testing universal vaccine for coronaviruses

Photo :Collected
Coronavirus chronicle

Pfizer and BioNTech Omicron-targeted vaccine delayed - BioNTech CEO

Pfizer, BioNTech start testing Omicron vaccine
Videos

Pfizer, BioNTech start testing Omicron vaccine

A doctor shows vials of Biontech-Pfizer's Comirnaty vaccine against Covid-19 at the Institute for Health and Food Safety of Zenica, Bosnia and Herzegovina, December 16, 2021. Photo :Reuters
Coronavirus chronicle

Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

Photo: Collected.
Coronavirus chronicle

Pfizer, BioNTech vaccine neutralises Omicron with three shots

The company said that it was interested in working exclusively with the government. Photo: Reuters
Coronavirus chronicle

Pfizer, BioNTech, Moderna making $1,000 profit every second: Analysis

FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski
Coronavirus chronicle

BioNTech sees up to 17 bln eur in vaccine revenue this year

A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
Coronavirus chronicle

US FDA advisers back Pfizer/BioNTech Covid-19 vaccine for children

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration
World+Biz

Civil society calls on candidates for German chancellor to waive intellectual property rules on Covid vaccines

FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski
Global Economy

BioNTech alone could lift German economy by 0.5% this year - economist

  • Show More
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]